Back to Report Store Home

Global Dermatology Market to 2022 – Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth

  • Published: May-2016
  • Report Code: GBIHC390MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Epidemiology Patterns for Atopic Dermatitis (Million), 2015–2022 16

Figure 2: Epidemiology Patterns for Acne Vulgaris (Million), 2015–2022 17

Figure 3: Epidemiology Patterns for Psoriasis (Million), 2015–2022 18

Figure 4: Dermatology, Global, Key Marketed Products and Approved Indications, 2015 25

Figure 5: Dermatology Therapeutics Market, Global, Annual Revenue for Humira ($bn), 2006–2022 27

Figure 6: Dermatology Therapeutics Market, Global, Annual Revenue for Remicade ($bn), 2006–2022 28

Figure 7: Dermatology Therapeutics Market, Global, Annual Revenue for Enbrel ($bn), 2006-2022 30

Figure 8: Dermatology Therapeutics Market, Global, Annual Revenue for Stelara ($bn), 2010–2022 31

Figure 9: Dermatology Therapeutics Market, Global, Annual Revenue for Neoral ($m), 2006–2022 33

Figure 10: Dermatology Therapeutics Market, Global, Annual Revenue for Protopic ($m), 2006–2022 34

Figure 11: Dermatology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016 39

Figure 12: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Stage of Development, Molecule Type and Program Type, 2016 41

Figure 13: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Stage of Development, 2016 42

Figure 14: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecule Type, 2016 43

Figure 15: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Molecular Target, 2016 44

Figure 16: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecular Target, 2016 45

Figure 17: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2016 46

Figure 18: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2016 47

Figure 19: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2016 48

Figure 20: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2016 49

Figure 21: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2016 50

Figure 22: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2016 51

Figure 23: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2016 52

Figure 24: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2016 53

Figure 25: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006–2016 54

Figure 26: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2016 55

Figure 27: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2016 56

Figure 28: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2016 57

Figure 29: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006–2016 58

Figure 30: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2016 59

Figure 31: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2016 60

Figure 32: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2016 61

Figure 33: Dermatology Global, Market Size ($bn), 2015–2022 62

Figure 34: Dermatology Global, Annual Revenue Forecast for Key Products ($bn), 2015–2022 64

Figure 35: Dermatology, Global, Annual Revenue Forecast for Tumor Necrosis Factor-Alpha Inhibitors ($bn), 2015–2022 67

Figure 36: Dermatology, Global, Annual Revenue Forecast for Interleukin Inhibitors ($bn), 2015–2022 68

Figure 37: Dermatology, Global, Annual Revenue Forecast for Calcineurin Inhibitors ($bn), 2015–2022 69

Figure 38: Dermatology, Global, Annual Revenue Forecast for Glucocorticosteroids ($m), 2015–2022 70

Figure 39: Dermatology, Global, Annual Revenue Forecast for Phosphodiesterase 4 inhibitors ($bn), 2015–2022 71

Figure 40: Dermatology Therapeutics Market, Global, Forecast Market Share by Company (%), 2015–2022 74

Figure 41: Dermatology, Global, Companies by Compound Annual Growth Rate (%), 2015–2022 75

Figure 42: Dermatology, Global, Revenues by Product Type, 2015–2022 76

Figure 43: Dermatology, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2015–2022 77

Figure 44: Dermatology, Global, AbbVie Annual Revenue Forecast ($bn), 2015–2022 78

Figure 45: Dermatology, Global, Amgen Annual Revenue Forecast ($bn), 2015–2022 79

Figure 46: Dermatology, Global, Novartis Annual Revenue Forecast ($bn), 2015–2022 80

Figure 47: Dermatology, Global, Roche Annual Revenue Forecast ($bn), 2015–2022 81

Figure 48: Dermatology, Global, Merck Annual Revenue Forecast ($bn), 2015–2022 82

Figure 49: Dermatology Therapeutics Market, Global, Revenue Forecast for ABP-501 ($m), 2015–2022 83

Figure 50: Dermatology Therapeutics Market, Global, Revenue Forecast for ixekizumab ($m), 2016–2022 84

Figure 51: Dermatology Therapeutics Market, Global, Revenue Forecast for dupilumab ($m), 2016–2022 85

Figure 52: Dermatology Therapeutics Market, Global, Revenue Forecast for AN-2728 ($m), 2016–2022 86

Figure 53: Dermatology Therapeutics Market, Global, Revenue Forecast for AMG-827 ($m), 2016–2022 87

Figure 54: Dermatology Therapeutics Market, Global, Revenue Forecast for guselkumab ($m), 2016–2022 88

Figure 55: Dermatology Therapeutics Market, Global, Cluster by Growth and Market Share, 2015–2022 90

Figure 56: Dermatology, Global, Companies by Type, 2016 92

Figure 57: Dermatology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Dermatology Specialization, 2016 93

Figure 58: Dermatology, Global, Proportion of Total Company Revenue Attributed to Dermatology, 2015–2022 94

Figure 59: Dermatology, Global, Licensing Deals, 2006–2016 96

Figure 60: Dermatology, Global, Licensing Deals by Indication, 2006–2016 97

Figure 61: Dermatology, Global, Licensing Deals, 2006–2016 98

Figure 62: Dermatology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006–2016 99

Figure 63: Dermatology, Global, Co-development Deals, 2006–2016 101

Figure 64: Dermatology, Global, Co-development Deals by Indication, 2006–2016 102

Figure 65: Dermatology, Global, Co-development Deals, 2006–2016 103

Figure 66: Dermatology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006–2016 104

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards